FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy

FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy


Signage is seen outside the U.S. Food and Drug Administration headquarters in White Oak, Maryland, Aug. 29, 2020.

Andrew Kelly | Reuters

The U.S. Food and Drug Administration has warned that some Tydemy birth control pills may not be effective, several days after the manufacturer recalled two batches of the medication that were distributed in the U.S.

The FDA said the pills in question could result in unexpected pregnancy. The agency has not received any reports of adverse events related to Tydemy so far.

related investing news

This little-known pharma stock can rally 50%, Citi says

CNBC Pro

The manufacturer, Lupin Pharmaceuticals, announced a voluntary recall of two batches of Tydemy on July 29. The pills in those batches were distributed in the U.S. between June 3, 2022, and May 31, 2023.

CNBC Health & Science

Read CNBC’s latest health coverage:

Lupin, in a statement last week, said it recalled the batches because pills in one batch tested low for ascorbic acid and “high for a known impurity.” The company said a significant reduction in ascorbic acid could affect the product’s effectiveness.

Lupin said it is notifying wholesalers, distributors, drug chains and supermarkets of the problem and is working to get the affected pills off store shelves. Any store, distributor or wholesaler that has the affected pills in stock should immediately stop distributing them, the company said.

The batches of Tydemy that may not be effective come from lot numbers L200183 and L201560.

Lupin advised patients to continue taking their medication and immediately consult with their doctor about an alternative form of contraception.



Source

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial
Health

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Analysts say […]

Read More
Dental supply stock rallies on theory RFK’s anti-fluoride stance will prompt more dentist visits
Health

Dental supply stock rallies on theory RFK’s anti-fluoride stance will prompt more dentist visits

Robert F. Kennedy Jr. attends a campaign event for Republican presidential nominee and former U.S. President Donald Trump in Milwaukee, Wisconsin, U.S. November 1, 2024.  Joel Angel Juarez | Reuters Dental care supplier Henry Schein advanced in Monday trading as investors bet that Robert F. Kennedy Jr., President-elect Donald Trump’s pick for Health and Human […]

Read More
2 health stocks are buys. They’ve been beaten up enough on Trump’s RFK Jr. pick for HHS
Health

2 health stocks are buys. They’ve been beaten up enough on Trump’s RFK Jr. pick for HHS

We are buying 25 shares of Danaher at roughly $229 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 550 shares of DHR, increasing its weighting to roughly 3.6% from 3.4%. The health care sector has been the big loser in the market since the election. If the SPDR Health Care Sector Fund , […]

Read More